Immunogenicity of 2 or 3 Doses of 9vHPV Vaccine in U.S. Female Individuals 15 to 26 Years of Age

Abbey B Berenson; Gitika Panicker; Elizabeth R Unger; Richard E Rupp; Yong-Fang Kuo

doi:10.1056/EVIDoa2300194

Immunogenicity of 2 or 3 Doses of 9vHPV Vaccine in U.S. Female Individuals 15 to 26 Years of Age

NEJM Evid. 2024 Feb;3(2):EVIDoa2300194. doi: 10.1056/EVIDoa2300194. Epub 2024 Jan 23.

Authors

Abbey B Berenson^{1

2}, Gitika Panicker³, Elizabeth R Unger³, Richard E Rupp^{2

4}, Yong-Fang Kuo^{2

5}

Affiliations

¹ Department of Obstetrics and Gynecology, The University of Texas Medical Branch, Galveston, TX.
² Center for Interdisciplinary Research in Women's Health, The University of Texas Medical Branch, Galveston, TX.
³ Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases at the Centers for Disease Control and Prevention, Atlanta.
⁴ Department of Pediatrics, The University of Texas Medical Branch, Galveston, TX.
⁵ Department of Biostatistics & Data Science, The University of Texas Medical Branch, Galveston, TX.

PMID: 38320488
DOI: 10.1056/EVIDoa2300194

Abstract

Immunogenicity of Two or Three Doses of 9vHPV VaccineThis noninferiority trial examined two versus three doses of 9-valent human papillomavirus (9vHPV) vaccine in individuals 15 to 26 years of age in the United States. In an unplanned interim analysis of female participants, two doses of 9vHPV vaccine appeared to elicit similar rates of seroconversion and antibody titers for each of the nine HPV genotypes to three doses at 1 month postvaccination.

MeSH terms

Antibodies, Viral
Female
Human Papillomavirus Viruses
Humans
Papillomavirus Infections* / prevention & control
Papillomavirus Vaccines*
Seroconversion
United States

Substances

Papillomavirus Vaccines
Antibodies, Viral